Cabaletta Bio, Inc. (CABA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 11, 2025, by Cabaletta Bio, Inc., a Delaware corporation. The filing discloses the termination of a material definitive agreement and the release of new clinical and translational data from the company's ongoing clinical trials for its lead asset, rese-cel (resecabtagene autoleucel).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific details regarding a terminated equity financing program:
- ATM Program Termination: The Company terminated its Sales Agreement with TD Securities (USA) LLC effective June 11, 2025.
- Shares Sold: 2,609,865 shares were sold under the program prior to termination.
- Gross Proceeds: $7,881,380.
- Remaining Capacity: $192,118,620 of shares remained available for sale at the time of termination.
- Termination Penalties: None.
Material Changes and Clinical Updates
The primary material change is the cessation of the ATM Program. Additionally, the Company presented new data from 18 evaluable patients across three trials (RESET-Myositis, RESET-SLE, and RESET-SSc) at the EULAR 2025 Congress:
- RESET-Myositis: 7 out of 8 patients achieved a clinical response off all immunomodulators. All 4 antisynthetase syndrome and dermatomyositis patients achieved a clinically meaningful total improvement score (TIS) response.
- RESET-SLE: 7 out of 7 patients achieved a clinical response off all immunomodulators and glucocorticoids. All non-renal SLE patients achieved remission (DORIS). The first lupus nephritis patient achieved DORIS and a complete renal response.
- RESET-SSc: Both patients in the severe skin cohort showed meaningful skin score improvements off immunomodulatory drugs. The first patient met CRISS criteria starting at 3 months.
- Enrollment Status: As of May 30, 2025, 51 patients are actively enrolled and 24 have been dosed.
Outlook, Risks, and Safety Profile
Management highlighted the potential for rese-cel to provide drug-free clinical responses. The safety profile across 18 patients with follow-up of 4 weeks or more included:
- Cytokine Release Syndrome (CRS): 94% of patients had no CRS or Grade 1 CRS (transient fever).
- Neurotoxicity (ICANS): 89% of patients had no ICANS. Two patients experienced previously reported ICANS events (one Grade 4 in SLE, one Grade 3 in SSc).
- Other Adverse Events: One patient in the SSc trial experienced a serious adverse event of neutropenic fever.
Investor Verification Checklist
- Verify the strategic rationale for terminating the $200 million ATM program with $192 million remaining capacity.
- Confirm the timeline for the next clinical data readouts and enrollment milestones for the RESET trials.
- Review the full text of the Press Release (Exhibit 99.1) for detailed statistical analysis of the clinical responses.
- Assess the long-term safety implications of the reported Grade 3 and Grade 4 ICANS events.
- Monitor cash runway given the termination of the ATM program and the capital-intensive nature of clinical development.